Selected Publications – LACTIN-V

LACTIN-V Phase 2b Bacterial Vaginosis Study Published in the New England Journal of Medicine

May 14, 2020 

A new article in the New England Journal of Medicine (NEJM) showed that LACTIN-V significantly reduced the recurrence of bacterial vaginosis (BV) in a Phase 2b study conducted at four sites in the U.S. The study was led by Craig Cohen, MD, MPH and Anke Hemmerling, MD, PhD, MPH of the University of California, San Francisco and supported by the National Institutes of Health (NIH). LACTIN-V represents the first microbiome-based drug to significantly reduce the recurrence of BV in an FDA-regulated trial.
read more

NEJM

Osel and Lactin-V Fertility Study Featured in GEN Magazine

A new article in Genetic Engineering and Biotechnology News (GEN) explores the role of a woman’s vaginal microbiome in infertility. The story features our collaborators in Denmark who have launched a study to determine if Lactin-V could be used to restore a more...

read more

Vaginal Microbiome Could Provide Clues to Pre-term Labor

Subtle changes to the microbiome in the vagina of pregnant women have been tied to pre-term labor in a recent study carried out by the Imperial College London. The study, published in the journal BMC Medicine, highlights the importance of the role of Lactobacillus...

read more

Nature Medicine Article Features Osel

Osel was featured in a recent article in Nature Medicine, “Living therapeutics: Scientist genetically modify bacteria to deliver drugs,” by Amy Maxmen. The article profiles our Director of Research Laurel Lagenaur and her work at Osel to investigate ways to manipulate bacteria to express HIV-inhibiting proteins, and other work to develop LACTIN-V, our live biotherapeutic drug candidate for bacterial vaginosis. Recent research has suggested that women with chronic bacterial vaginosis are more susceptible to HIV.

read more